Exhaled Nitric Oxide Reflects the Immune Reactions of the Airways in Early Rheumatoid ArthritisShow others and affiliations
2024 (English)In: Biomedicines, E-ISSN 2227-9059, Vol. 12, no 5, article id 964Article in journal (Refereed) Published
Abstract [en]
Patients with rheumatoid arthritis (RA) have altered levels of exhaled nitric oxide (NO) compared with healthy controls. Here, we investigated whether the clinical features of and immunological factors in RA pathogenesis could be linked to the NO lung dynamics in early disease. A total of 44 patients with early RA and anti-citrullinated peptide antibodies (ACPAs), specified as cyclic citrullinated peptide 2 (CCP2), were included. Their exhaled NO levels were measured, and the alveolar concentration, the airway compartment diffusing capacity and the airway wall concentration of NO were estimated using the H & ouml;gman-Meril & auml;inen algorithm. The disease activity was measured using the Disease Activity Score for 28 joints. Serum samples were analysed for anti-CCP2, rheumatoid factor, free secretory component, secretory component containing ACPAs, antibodies against Porphyromonas gingivalis (Rgp) and total levels of IgA, IgA1 and IgA2. Significant negative correlations were found between the airway wall concentration of NO and the number of swollen joints (Rho -0.48, p = 0.004), between the airway wall concentration of NO and IgA rheumatoid factor (Rho -0.41, p = 0.017), between the alveolar concentration and free secretory component (Rho -0.35, p = 0.023) and between the alveolar concentration and C-reactive protein (Rho -0.36, p = 0.016), but none were found for anti-CCP2, IgM rheumatoid factor or the anti-Rgp levels. In conclusion, altered NO levels, particularly its production in the airway walls, may have a role in the pathogenesis of ACPA-positive RA.
Place, publisher, year, edition, pages
MDPI , 2024. Vol. 12, no 5, article id 964
Keywords [en]
rheumatoid arthritis; free secretory component; ACPA; exhaled nitric oxide; lung; pathogenesis; rheumatoid factor
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-204359DOI: 10.3390/biomedicines12050964ISI: 001232352600001PubMedID: 38790926OAI: oai:DiVA.org:liu-204359DiVA, id: diva2:1868728
Note
Funding Agencies|Centre for Research and Development, Uppsala University/Region Gavleborg; Gavle Cancer Foundation; King Gustaf V's 80-year Foundation [FAI-2021-0771]; Swedish Rheumatism Foundation [R-969194]; US NIH/NIDCR [DE 022597]; National Science Center, NCN, Krakow, Poland [UMO-2018/30/A/NZ5/00650]
2024-06-122024-06-122025-02-18